Back to list

Investigating whether TOL-3021 can stop autoimmune pancreatic beta cell attack in adults with recently diagnosed Type I Diabetes

University of North Carolina at Chapel Hill


This study investigates whether TOL-3021 can stop the autoimmune pancreatic beta cell attack in adults with recently diagnosed Type I Diabetes.


Auto Immune Diseases, Diabetes


Drug or Biologic



18 - 40 years


Study Population

Adults 18-40 yo with new-onset Type I Diabetes (less than 5 years)


John Buse
Verne S. Caviness Distinguished Prof

For questions, contact:

Alex Kass
(984) 974-3009

Recruitment Period End

October 2, 2020


Primary Location
UNC Diabetes Care Center - Clinical Trials
300 Meadowmont Village Cir, Chapel Hill, NC 27517, USA

Study Qualifications

Gender Any

Age Range 18 - 40 years

Participant qualification(s) Diagnosed with Type I Diabetes within last 5 years; Hemoglobin A1c level <7.6%; on insulin therapy; willingness to wear Dexcom G6 continuous glucose monitoring device throughout trial

Not eligible if: BMI>32kg/m^2; Pregnant or breastfeeding; Previous immunotherapy for T1DM; Liver disease; kidney disease; cardiac disease; history of organ transplant including beta cell transplant; history of adrenal insufficiency

Number of Visits

    » 22 In person visit(s)

    22 clinic visits including 1 screening, 4 eye exams

    » 0 Remote visit(s)

Participation Period

42 months


$100 gift card per completed clinic visit

By clicking I am interested, your contact information will be sent to the researcher/study coordinator for this study. The coordinator will respond by email with additional information on how to proceed.